SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · IEX Real-Time Price · USD
4.290
-0.120 (-2.72%)
Apr 19, 2024, 4:30 PM EDT - Market closed
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 15.5, with a low estimate of 6.00 and a high estimate of 25. The average target predicts an increase of 261.31% from the current stock price of 4.29.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SABS stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +39.86% | Apr 16, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +482.75% | Apr 16, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3 → $25 | Strong Buy | Maintains | $3 → $25 | +482.75% | Apr 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +39.86% | Apr 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1 → $10 | Strong Buy | Reiterates | $1 → $10 | +133.10% | Jan 8, 2024 |
Financial Forecast
Revenue This Year
n/a
from 2.24M
Revenue Next Year
n/a
EPS This Year
-5.00
from -7.64
EPS Next Year
-6.33
from -5.00
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | n/a | n/a |
| Avg | n/a | n/a |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -5.15 | -6.52 |
| Avg | -5.00 | -6.33 |
| Low | -4.80 | -6.09 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.